Evidence map›Paper›PMID 35773357›Full record

Trial reportWorld journal of urology2022

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

Mostafa AbdelRazek, Ahmad Abolyosr, Omar Mhammed, Atef Fathi, Mohammed Talaat, Ahmed Hassan

Erratum issuedOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mostafa AbdelRazekUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt. mostafa_uro@yahoo.com.ORCID http://orcid.org/0000-0002-9941-0784
Ahmad AbolyosrUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt.
Omar MhammedUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt.
Atef FathiUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt.
Mohammed TalaatUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt.
Ahmed HassanUrology Department, Qena University Hospital, South Valley University, Qena, P.O: 83523, Egypt.
South Valley University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMen with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), will have deterioration in the quality of life. Likewise, BPH can be complicated by damage to bladder function, bladder stones formation, hematuria, and impaired kidney function. The goal of treatment is to avoid all those effects caused by BPH.

objectiveTo evaluate the efficacy of tadalafil alone, silodosin alone, and the combination of both in the treatment of LUTS associated with BPH. PATIENTS AND

methodsPatients in our department with BPH who had LUTS were assigned randomly to three groups: A (101 patients) received tadalafil, 5 mg; B (102 patients) received silodosin, 8 mg; and group C (105 patients) received the combination of tadalafil, 5 mg, and silodosin, 8 mg. For all participants, we asses changes in the maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), International Index of Erectile Function (IIEF) score, Post-voiding urine (PVR) and all results were recorded and analyzed with the (SPSS) and Microsoft Excel 2010.

resultsQmax, IPSS, PVR and IIEF score improved significantly more with the combination of tadalafil and silodosin than with either drug alone (p < 0.001). Three months after treatment, the mean Qmax values were 14.4 ml/sec in group A, 15.2 ml/sec in group B, and 15.8 ml/sec in group C; and the mean IPSSs were 17.6 in group A, 16.7 in group B, and 15.6 in group C (p < 0.001).

conclusionTadalafil and silodosin are effective treatment options in men with BPH who have LUTS, but the combination of both is more effective and feasible in treating LUTS of BPH.

Indexed as

Erectile DysfunctionLower Urinary Tract SymptomsProstatic HyperplasiaHumansIndolesMalePhosphodiesterase 5 InhibitorsProspective StudiesQuality of LifeTadalafilTreatment OutcomeIndolesPhosphodiesterase 5 InhibitorssilodosinTadalafilBenign prostatic hyperplasiaLower urinary tract symptoms of BPHSilodosinTadalafil

Identifiers

PMID35773357
PMCPMC9279271
OpenAlexW4283729733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.